ArticleMolecular medicine (Cambridge, Mass.)2025
YULINK deficiency promotes cell death under glucose restriction in HCC cells in association with GLUT1-mediated glycolysis.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThrough evolutionary genomics analysis, we identified Yulink (MIOS, Entrez Gene: 54,468), a highly conserved gene encoding an 875 amino acid protein with diverse functions in humans. Given the importance of accelerated glycolysis in hepatocellular carcinoma (HCC), we explored the expression and function of Yulink in HCC cells and analyzed clinicopathological data to unveil its impact on patient survival.
methodsClinicopathological data from 184 patients with resectable HCC were mined to establish a correlation between Yulink expression and patient survival. We employed reverse transcription quantitative polymerase chain reaction (RT-qPCR) to assess Yulink expression in the tumor tissues. Various assays, including Western blotting, migration, MTT, cell cycle, immunofluorescence, oxidative stress, tumorigenesis, glucose uptake, glycolytic function, proximity ligation, and immunoprecipitation, were conducted on Huh7 cells to identify the regulatory mechanisms under glucose restriction.
resultsComparative evolutionary genomics analysis revealed that patients with high Yulink expression had significantly shorter relapse-free survival (RFS) and overall survival (OS) (P < 0.0001 and = 0.0015, respectively). Multivariable Cox regression analysis identified Yulink expression as an independent unfavorable predictor of RFS (HR, 2.63; 95% CI, 1.58-4.38; P < 0.001) in HCC. Furthermore, Yulink expression positively correlated with Huh7 migration and survival, especially in response to glucose restriction. Yulink deficiency enhanced glucose restriction-induced cell death, likely due to increased reactive oxygen species (ROS) and DNA damage, with a failure of ATM-CHK2 activation. Huh7 xenografts with Yulink suppression exhibited delayed tumorigenesis in immunocompromised nude mice. Importantly, proximity Ligation assays and immunoprecipitation demonstrated that Yulink colocalized and interacted with glucose transporter 1 (GLUT1). Knockdown of Yulink not only suppressed GLUT1 expression, but also disrupted GLUT1 translocation from the cytosol to the cell membrane, resulting in downregulated glucose uptake and glycolysis.
conclusionsOur results underscore the protective role of Yulink in HCC survival under glucose restriction and its pivotal function in glucose metabolism, suggesting a mechanistic link between lower Yulink expression and higher survival in patients with HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.